Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
poison centers have reported an uptick of medical issues linked to compounded GLP-1 drugs
Both options include provider supervision, 503A compounded medication from a licensed pharmacy, dosing instructions, and follow-up
Whilst the market is currently led by Novo Nordisks semaglutide (Ozempic/Wegovy) and Eli Lillys tirzepatide (Mounjaro/Zepbound), stronger competition is expected with new entrants (Boehringer Ingelheim, Amgen, Pfizer, Roche amongst others) offering novel mechanisms (dual agonists, triple agonists and amylins), formulations (oral vs injectable) and dosing regimens (daily vs weekly vs monthly).
(Figure 4A)
.jpg_11.jpeg)
US$ 23.21
US$ 29.01
US$ 20.79
US$ 23.32
US$ 21.56
US$ 20.56
US$ 29.52
US$ 26.41
